Skip to main content

Advertisement

Table 1 Patients and Bisphosphonate Therapy Characteristics

From: Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws

Authors/Study Gender Age Comorbidities Medications (Years)
Marunick et al. [4] CS Patient 1 F 59 OST STE + METX + AL (3)
Yarom et al. [6] RS     
Patient 2 F 73 HTN STE + METX + AL (7), infliximab
Patient 3 F 76 HTN + Arrhythmia + hypercholesterolemia AL (1.5)
Malden & Pai [7] CS Patient 4 F 56 NO STE + AL (1), leflunomide
Khamaisi et al. [8] RS Patient 5 F 73 DM AL (> 0,5)
Marx et al. [9] CS     
Patient6 F NA OST STE + METX + AL (3.1)
Patient 7 F NA OST STE + METX + AL (6.3)
Patient 8 F NA OST STE + METX + AL (3.3)
Hamada [10] CR     
Patient 9 F 68 OST STE + RISE (4)
Barrow [11] CR     
Patient 10 F 70 OST STE + AL (< 3)
Junquera et al. [12] CS     
Patient 12a/12b M 73 NO STE + METX + AL (3.8)
Mehanna et al. [13] CR     
Patient 13 F 55 NO STE + Leflunomide + oral BPs (1)
Favia et al. [14] CS     
Patient 14a/14b F 67 OST STE + IBAN (1)
Kwon et al. [15] CR     
Patient 15 F 71 OST + DM STE + AL (3); OH
Sedghizadeh et al. [16] RS     
Patient 16 F 63 OST + HTN STE + chemotherapy + AL (3)
Lo et al. [17] RS     
Patient 17 NA NA NO oral BPs (4.8)
Patient 18 NA NA Hip Osteonecrosis STE + oral BPs (2.6)
Shin et al. [18] CR     
Patient 19 F 67 OST + HTN AL (1) + HTN Drug
Park et al. [19] CS     
Patient 20 F 68 OST STE + AL (5)
Patient 21 F 69 OST + PLE + TB STE + AL (10)
Patient 22 F 70 OST + HTN STE + AL (6)
Manfredi et al. [20] CS     
Patient 23 F 68 OST + DM + HTN AL (4.25)
Patient 24 F 65 OST + HTN AL (5)
Patient 25 F 79 OST AL (4)
Patient 26 F 57 OST + DM + HTN AL (> 3)
Conte-Neto et al. [21] CR     
Patient 27 F 58 NO AL (5)
Patient 28 F 68 OST STE + METX + AL (7)
  1. CS Case series, RS Retrospective study, CR Case report, NA Not available
  2. OST Osteoporosis, HTN Hypertension, DM, Diabetes Mellitus, GU gastric ulcer, PLE Pleuritis, TB Tuberculosis, STE Steroids, MTX Methotrexate; AL Alendronate, RISE Risedronate, IBAN Ibandronate, OH oral hypoglycemiant